Glyriva Bexicap

Glyriva Bexicap

Glyriva Bexicap

Generic Name: Glycopyrronium
Dosage Form: Dry Powder Inhaler/Capsule
TG Name: Respiratory

What is Glyriva® Bexicap?
Glyriva® Bexicap capsule contains Glycopyrronium bromide INN as the active ingredient which is a long-acting, antimuscarinic agent which has to be taken by a Dry Powder Inhaler Device. Glyriva is indicated as maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).
How Glyriva® Bexicap works?
Glyriva® is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) for once-daily maintenance bronchodilator treatment of COPD. Parasympathetic nerves are the major bronchoconstrictive neural pathway in airways. Glycopyrronium works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells. Glycopyrronium bromide is a high affinity muscarinic receptor antagonist. A greater than 4-fold selectivity for the human M3 receptors over the human M2 receptor has been shown.

What are the Indication of Glyriva® Bexicap?
Glyriva® Bexicap is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).

What are the Dosage and Administration of Glyriva® Bexicap??
Adult over 18 years: The recommended dose of Glyriva® Bexicap capsule is 50 mcg (1 capsule) once-daily, with the Bexihaler device taken at the same time every day.
The contents of the Glyriva® Bexicap capsules are only for oral inhalation and should only be used with the Bexihaler device.
No dosage adjustment is required for geriatric, hepatically-impaired, or renally-impaired patients. However, patients with moderate to severe renal impairment given Glyriva® Bexicap capsule should be monitored closely for anticholinergic effects.

What are the Contraindication of Glyriva® Bexicap?
Glyriva® Bexicap is contraindicated in patients with hypersensitivity to any of the ingredients or allergic to Glycopyrronnium.

What are the Side effects of Glyriva® Bexicap? The most commonly reported adverse drug reaction is dry mouth. Dry mouth is usually mild and often resolved during continued treatment. Other reactions reported in individual patients and consistent with possible anticholinergic effects included constipation, increased heart rate, blurred vision, glaucoma, urinary difficulty, and urinary retention.

What would be the storage condition of Glyriva® Bexicap?

  • Keep this medicine out of the sight and reach of children.
  • Do not use this medicine after the expiry date which is stated on the carton and blister after “EXP”. The expiry date refers to the last day of that month.
  • Do not store above 25°C.
  • Store the capsules in the original blister in order to protect from moisture. Do not remove from the blister until immediately before use. Each inhaler should be disposed of after 30 days of use.
  • Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.
  • Do not throw away any medicines via wastewater or household waste.
  • Ask your pharmacist how to throw away medicines you no longer use.